Evidence map›Paper›PMID 40691743›Full record

ReviewSurgery today2025

Living donor liver transplantation using ABO-incompatible grafts for chronic and acute liver failure.

Toru Ikegami, Masashi Tsunematsu, Kenei Furukawa, Shinji Onda, Michinori Matsumoto, Yoshihiro Shirai, Koichiro Haruki

Abstract readReview
PubMed Publisher
In one paragraph

Review in Surgery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Toru IkegamiDivision of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, 105-8461, Japan. toruikegamijikei@jikei.ac.jp.
Masashi TsunematsuDivision of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.
Kenei FurukawaDivision of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.
Shinji OndaDivision of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.
Michinori MatsumotoDivision of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.
Yoshihiro ShiraiDivision of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.
Koichiro HarukiDivision of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.

Funding

Kakenhi (Grants-in-Aid for Scientific Research) 24K11898
6 · The paper itself

Abstract

The introduction of rituximab, an anti-CD20 antibody, has changed the treatment strategies and outcomes for ABO-incompatible living donor liver transplantation (ABOi-LDLT) dramatically. Rituximab targets the CD20-positive B-cells that would differentiate into plasma cells, producing antibodies against A or B antigen-expressing cells and causing microvascular multiple thrombosis and graft necrosis or diffuse bile-duct necrosis. Now, the universal desensitization of the ABOi combination between the donor and recipient is performed by rituximab, and ABOi-LDLT has become the treatment of choice for end-stage liver disease. However, because rituximab takes 1-3 weeks to mediate its effects, complicated strategies are necessary to perform ABOi-LDLT for acute liver failure. For example, high-dose intravenous immunoglobulin (IVIG) or bortezomib may be used to alleviate the elevation of isoagglutinin titers. The diagnosis and treatment of antibody-mediated rejection (AMR) remain challenging. Treatment options include plasma exchange, high-dose IVIG, and bortezomib, but the optimal strategies have not been identified. In this review, we discuss standard ABOi-LDLT for chronic liver disease, ABOi-LDLT for acute liver failure, and the diagnosis and treatment of AMR.

Indexed as

ABO Blood-Group SystemBlood Group IncompatibilityEnd Stage Liver DiseaseLiver Failure, AcuteLiver TransplantationLiving DonorsBortezomibChronic DiseaseGraft RejectionHumansImmunoglobulins, IntravenousPlasma ExchangeRituximabABO Blood-Group SystemBortezomibImmunoglobulins, IntravenousRituximabBlood type incompatibleLiving donor liver transplantationRituximab

Identifiers

PMID40691743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.